Bank of New York Mellon Corp Trims Position in National Research Corporation (NASDAQ:NRC)

Bank of New York Mellon Corp cut its holdings in shares of National Research Corporation (NASDAQ:NRC) by 3.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 209,197 shares of the company’s stock after selling 8,015 shares during the period. Bank of New York Mellon Corp owned 0.91% of National Research worth $2,678,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Azzad Asset Management Inc. ADV purchased a new position in shares of National Research during the first quarter valued at about $426,000. Willis Investment Counsel increased its position in shares of National Research by 19.1% during the first quarter. Willis Investment Counsel now owns 65,778 shares of the company’s stock valued at $842,000 after buying an additional 10,531 shares during the period. Rhumbline Advisers increased its position in shares of National Research by 4.5% during the first quarter. Rhumbline Advisers now owns 22,204 shares of the company’s stock valued at $284,000 after buying an additional 946 shares during the period. GAMMA Investing LLC increased its position in shares of National Research by 45,978.8% during the first quarter. GAMMA Investing LLC now owns 15,206 shares of the company’s stock valued at $195,000 after buying an additional 15,173 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in National Research by 3.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,565 shares of the company’s stock worth $680,000 after purchasing an additional 1,148 shares during the period. 47.26% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Patrick E. Beans purchased 2,500 shares of National Research stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average cost of $13.59 per share, with a total value of $33,975.00. Following the completion of the purchase, the insider directly owned 35,003 shares in the company, valued at approximately $475,690.77. This trade represents a 7.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by insiders.

National Research Price Performance

Shares of NRC stock opened at $13.89 on Monday. The stock has a market cap of $316.41 million, a price-to-earnings ratio of 13.49 and a beta of 0.45. The business’s fifty day moving average is $15.35 and its 200 day moving average is $14.75. National Research Corporation has a twelve month low of $9.76 and a twelve month high of $27.07. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 1.98.

National Research (NASDAQ:NRC) last issued its quarterly earnings results on Monday, April 28th. The company reported $0.25 earnings per share for the quarter. The company had revenue of $33.55 million for the quarter. National Research had a return on equity of 71.33% and a net margin of 17.14%.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.